Trial Profile
A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms HORIZON 2
- Sponsors Janssen Vaccines and Prevention B.V
- 11 Oct 2023 Status changed from active, no longer recruiting to completed.
- 19 Jul 2023 Planned primary completion date changed from 18 Oct 2022 to 14 Aug 2023.
- 22 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm decreases from 12 to 6, phase changes from 2/3 to phase 2.